IP Library Granted Patent US 8,114,968
Granted Patent B2
US 8,114,968 · App. 12/397,258 · Granted Feb 14, 2012

Metalloproteinase-12 specific monoclonal antibody

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,114,968
App. No.
12/397,258
Granted
Feb 14, 2012
Kind
B2
Abstract

Proteins that bind to matrix metalloproteinase 12 and methods of using such proteins are described.

Claims (11)

1. An isolated Matrix Metalloproteinase-12 (MMP-12) specific monoclonal antibody, wherein the monoclonal antibody binds an epitope bound by an antibody having a heavy chain (HC) immunoglobulin variable domain sequence of SEQ ID NO. 1825 and a light chain (LC) immunoglobulin variable domain sequence of SEQ ID NO: 608.

2. The monoclonal antibody of claim 1 , wherein the monoclonal antibody binds human MMP-12.

3. The monoclonal antibody of claim 1 , wherein the monoclonal antibody inhibits the catalytic activity of MMP-12.

4. The monoclonal antibody of claim 1 , wherein the monoclonal antibody guides a nano-particle or toxin to a cell expressing MMP-12 on the cell surface.

5. The monoclonal antibody of claim 1 , wherein

the HC immunoglobulin variable domain sequence comprises a CDR1, CDR2 and CDR3 having the amino acid sequence of SEQ ID NO: 14, SEQ ID No. 936, and SEQ ID NO: 995, respectively; and

the LC immunoglobulin variable domain sequence comprises a CDR1, CDR2 and CDR3 having the amino acid sequence of SEQ ID NO: 84, SEQ ID NO: 152, and SEQ ID NO: 220, respectively.

6. The monoclonal antibody of claim 1 , wherein the monoclonal antibody comprises the light and heavy chains of SEQ ID NO:608 and SEQ ID NO: 1825, respectively.

7. A pharmaceutical composition comprising an MMP-12 specific monoclonal antibody of claim 1 and a pharmaceutically acceptable carrier.

8. The monoclonal antibody of claim 5 , wherein the monoclonal antibody comprises the light chain of SEQ ID NO: 608.

9. The monoclonal antibody of claim 5 , wherein the monoclonal antibody comprises the light chain of SEQ ID NO: 1825.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 18, 2021
From: DYAX CORP.
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 056268/0983 →